• Clinical Data

Summit, Akeso’s ivonescimab bests Merck’s Keytruda in China trial–again

pharminent September 3, 2026

• M&A / Deals

Boehringer signs AI drug discovery deal with Owkin

pharminent September 3, 2026

• M&A / Deals

Novartis signs $3.2bn drug delivery deal with Alteogen

pharminent September 3, 2026

• News

UK Suspends Amgen’s Tavneos for New Patients as a Data-Integrity Cascade Spreads Across Three Regulators

pharminent September 2, 2026

• Clinical Data

Autoimmune CAR-T faces tough questions after Novartis, Bristol Myers study halts

pharminent September 2, 2026

• Pipeline

Beyond GLP1s: The race for nextgen obesity drugs starts in the preclinical models

pharminent September 2, 2026

• Market Access

Tavneos no longer available for new patients in UK as Amgen awaits FDA hearing

pharminent September 2, 2026

• M&A / Deals

Ono Pharmaceutical joins forces with Aitia for drug discovery in neurology

pharminent September 2, 2026

• Manufacturing

US puts $125m into personalised RNA therapy production

pharminent September 2, 2026

• Other

Takeda and Weave Bio collaborate on AI-driven automation in drug development

pharminent September 2, 2026

• News

Novartis Posts Phase 3 MS Win and Halts Eight Autoimmune CAR-T Trials

pharminent September 1, 2026

• Policy / Pricing

Mid-cap biotechs join Trump’s latest round of drug pricing deals

pharminent September 1, 2026

• Clinical Data

Novartis says MS pill succeeds in two large studies

pharminent September 1, 2026

• News

Lilly Pays Up to $2.875 Billion for Merida and a Phase 1 Autoantibody Platform

pharminent August 31, 2026

• Regulatory

FDA OKs Takeda, Protagonist drug for rare blood cancer

pharminent August 31, 2026

• M&A / Deals

Lilly adds to immune drug pipeline with $2.9B Merida buyout

pharminent August 31, 2026

• Regulatory

FDA clears Takeda, Protagonist’s first-in-class PV drug

pharminent August 31, 2026

• Clinical Data

ESC 2026: Evolocumab explores new frontiers in CV disease prevention

pharminent August 31, 2026

• M&A / Deals

Acquisitive Lilly offers $2.88bn for Merida Bio

pharminent August 31, 2026

• News

FDA Approves Mounjaro Label Expansion to Reduce Cardiovascular Risk in Type 2 Diabetes

pharminent August 28, 2026

• Regulatory

FDA green lights Priovant drug for rare skin disease

pharminent August 28, 2026

• Manufacturing

Multispecifics are transforming the CDMO development architecture

pharminent August 28, 2026

• News

FDA Approves Priovant’s LISRAYA (Brepocitinib), the First Targeted Therapy for Dermatomyositis

pharminent August 28, 2026

• Clinical Data

New data could widen use of AstraZeneca, Amgen immune disease drug

pharminent August 27, 2026

• Policy / Pricing

MFN sparks defiance from Europe’s larger nations, uncertainty among smaller ones

pharminent August 27, 2026

• News

FDA Approves Revolution Medicines’ Rasonque, First RAS(ON) Inhibitor for Metastatic Pancreatic Cancer

pharminent August 26, 2026

• Clinical Data

Spyre deprioritises arthritis drug after Phase 2 results

pharminent August 26, 2026

• M&A / Deals

Metsera backers establish new biotech armed with China-licensed immunology asset

pharminent August 26, 2026

• Regulatory

Neurocrine receives FDA IND Acceptance for Alzheimer’s Ph2

pharminent August 26, 2026

• Regulatory

Jazz secures FDA approval for Ziihera in advanced HER2+ GEA

pharminent August 26, 2026

• M&A / Deals

McKesson to acquire Precision Medicine Group for $2.25bn

pharminent August 26, 2026

• News

FDA Approves J&J’s Imaavy for Warm Autoimmune Hemolytic Anemia, the First Therapy Ever Cleared in the Disease

pharminent August 25, 2026

• Regulatory

Roche, Eli Lilly get FDA nod for new Alzheimer’s blood test

pharminent August 25, 2026

• M&A / Deals

China’s Haisco forms immunology biotech with up to $1.5B from American VCs

pharminent August 25, 2026

• Regulatory

Expanded US Imaavy approval first ever for wAIHA

pharminent August 25, 2026

• Pipeline

Bausch + Lomb advances dry eye disease drug to Phase 3 despite mid-stage fail

pharminent August 25, 2026

• Regulatory

FDA greenlights Roche’s biomarker blood test for Alzheimer’s

pharminent August 25, 2026

• Regulatory

FDA places clinical hold on Regenxbio’s RGX-121 in MPS II trial

pharminent August 25, 2026

• News

Genentech Licenses Hanmi’s Muscle-Sparing Obesity Drug in Deal Worth Up to $2.3 Billion

pharminent August 24, 2026

• Regulatory

Capricor’s Duchenne therapy has new life after FDA grants 3-month extension

pharminent August 24, 2026